跳转至内容
Merck
CN
  • Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Journal of virology (2014-10-10)
Michael Wolferstätter, Marc Schweneker, Michaela Späth, Susanne Lukassen, Marieken Klingenberg, Kay Brinkmann, Ursula Wielert, Henning Lauterbach, Hubertus Hochrein, Paul Chaplin, Mark Suter, Jürgen Hausmann
摘要

Double-stranded RNA (dsRNA) is an important molecular pattern associated with viral infection and is detected by various extra- and intracellular recognition molecules. Poxviruses have evolved to avoid producing dsRNA early in infection but generate significant amounts of dsRNA late in infection due to convergent transcription of late genes. Protein kinase R (PKR) is activated by dsRNA and triggers major cellular defenses against viral infection, including protein synthesis shutdown, apoptosis, and type I interferon (IFN-I) production. The poxviral E3 protein binds and sequesters viral dsRNA and is a major antagonist of the PKR pathway. We found that the highly replication-restricted modified vaccinia virus Ankara (MVA) engineered to produce excess amounts of dsRNA early in infection showed enhanced induction of IFN-β in murine and human cells in the presence of an intact E3L gene. IFN-β induction required a minimum overlap length of 300 bp between early complementary transcripts and was strongly PKR dependent. Excess early dsRNA produced by MVA activated PKR early but transiently in murine cells and induced enhanced systemic levels of IFN-α, IFN-γ, and other cytokines and chemokines in mice in a largely PKR-dependent manner. Replication-competent chorioallantois vaccinia virus Ankara (CVA) generating excess early dsRNA also enhanced IFN-I production and was apathogenic in mice even at very high doses but showed no in vitro host range defect. Thus, genetically adjuvanting MVA and CVA to generate excess early dsRNA is an effective method to enhance innate immune stimulation by orthopoxvirus vectors and to attenuate replicating vaccinia virus in vivo. Efficient cellular sensing of pathogen-specific components, including double-stranded RNA (dsRNA), is an important prerequisite of an effective antiviral immune response. The prototype poxvirus vaccinia virus (VACV) and its derivative modified vaccinia virus Ankara (MVA) produce dsRNA as a by-product of viral transcription. We found that inhibition of cellular dsRNA recognition established by the virus-encoded proteins E3 and K3 can be overcome by directing viral overexpression of dsRNA early in infection without compromising replication of MVA in permissive cells. Early dsRNA induced transient activation of the cellular dsRNA sensor protein kinase R (PKR), resulting in enhanced production of interferons and cytokines in cells and mice. Enhancing the capacity of MVA to activate the innate immune system is an important approach to further improve the immunogenicity of this promising vaccine vector.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙二胺四乙酸, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
尿嘧啶, ≥99.0%
Sigma-Aldrich
乙二胺四乙酸, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
乙二胺四乙酸 溶液, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
乙二胺四乙酸 二钠盐 溶液, BioUltra, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
乙二胺四乙酸, 99.995% trace metals basis
Sigma-Aldrich
乙二胺四乙酸, BioUltra, anhydrous, ≥99% (titration)
Sigma-Aldrich
二氟氢化铵, reagent grade, 95%
Sigma-Aldrich
乙二胺四乙酸, purified grade, ≥98.5%, powder
Supelco
尿嘧啶, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
N,N′ 双(丙烯酰)胱胺, BioReagent, suitable for electrophoresis
Sigma-Aldrich
尿嘧啶, BioReagent, suitable for cell culture
Sigma-Aldrich
乙二胺四乙酸, ≥98.0% (KT)
Sigma-Aldrich
乙二胺四乙酸, BioUltra, ≥99.0% (KT)
Sigma-Aldrich
单克隆抗 β-微管蛋白 I 小鼠抗, clone SAP.4G5, ascites fluid
Sigma-Aldrich
乙二胺四乙酸, Vetec, reagent grade, 98%
氟尿嘧啶杂质C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
尿嘧啶, Vetec, reagent grade, 98%